# Semaglutide FAQ: Heart, Dosing, Side Effects and More

> Semaglutide questions answered from the trial record: heart and stroke risk, the SELECT and SUSTAIN-6 results, dosing, side effects, half-life, oral vs injection, and more.

Short, sourced answers to what people most often ask — each tied to a study where it makes a number.

## Is semaglutide good for the heart?

The trial record points that way in the populations studied. In SELECT, in adults with established heart disease and excess weight but no diabetes, once-weekly semaglutide 2.4 mg cut major cardiovascular events by 20% versus placebo (HR 0.80; 95% CI 0.72-0.90) [3]. In SUSTAIN-6, in type 2 diabetes at high risk, the same composite fell about a quarter (HR 0.74) [2]. These are population results, not individual guarantees.

## Does semaglutide reduce the risk of heart attack and stroke?

In the trials, yes, as part of a bundled endpoint. SELECT measured a composite of cardiovascular death, nonfatal heart attack and nonfatal stroke and found a 20% reduction with once-weekly semaglutide 2.4 mg versus placebo (HR 0.80; 95% CI 0.72-0.90; P<0.001) [3]. SUSTAIN-6 showed a similar direction in type 2 diabetes (HR 0.74; 95% CI 0.58-0.95) [2]. The trials report the combined endpoint rather than each event in isolation.

## What were the results of the SELECT cardiovascular trial?

SELECT enrolled 17,604 adults with preexisting cardiovascular disease and overweight or obesity but without diabetes. Once-weekly semaglutide 2.4 mg reduced the primary composite of cardiovascular death, nonfatal heart attack and nonfatal stroke by 20% versus placebo (HR 0.80; 95% CI 0.72-0.90; P<0.001) [3]. A 2024 secondary analysis confirmed the benefit and found it independent of baseline blood-sugar status [13].

## What is semaglutide?

Semaglutide is a long-acting GLP-1 receptor agonist — a 31-amino-acid peptide modeled on the gut hormone GLP-1, engineered to resist breakdown and last about a week [17]. It is an approved medicine for type 2 diabetes, chronic weight management, cardiovascular-risk reduction in established heart disease, and, since 2025, a fatty-liver condition. In STEP 1 it produced a mean weight change of -14.9% over 68 weeks [1].

## What is semaglutide used for?

It is approved for type 2 diabetes, for long-term weight management, for reducing major cardiovascular events in adults with established cardiovascular disease and excess weight, and (2025) for metabolic dysfunction-associated steatohepatitis (MASH), a serious fatty-liver disease. In STEP 1, once-weekly 2.4 mg produced a mean body-weight change of -14.9% versus -2.4% on placebo over 68 weeks [1], and in SELECT it cut major cardiovascular events by 20% [3].

## How does semaglutide work?

It activates the GLP-1 receptor, copying a gut hormone: it boosts glucose-dependent insulin release, suppresses glucagon, slows the stomach, and acts on brain appetite circuits to reduce hunger [5]. In rodents it reached the brainstem and hypothalamus to lower food intake and shift food preference without reducing energy expenditure [4]. An engineered design lets it last about a week per dose [17].

## How does semaglutide work for weight loss?

The weight effect is mainly central — it reduces appetite rather than raising calorie burn. In rodents, semaglutide acted on hypothalamic and brainstem appetite circuits to cut food intake and alter food preference, with no fall in energy expenditure [4]. The human result that follows is the -14.9% mean weight change measured over 68 weeks in STEP 1 versus -2.4% on placebo [1].

## What is the semaglutide dosage for weight loss?

In STEP 1, the studied weight-management regimen was once-weekly subcutaneous semaglutide escalated to a 2.4 mg maintenance dose, which produced a mean body-weight change of -14.9% over 68 weeks versus -2.4% on placebo [1]. That figure is study-attributed and is not a personal recommendation; dosing decisions belong to a prescriber. The documented titration is detailed on [the dosage page](/dosage).

## How many mg is 40 units of semaglutide?

This site does not provide unit-to-milligram conversions or any individual dosing guidance, because such conversions depend on a specific product's concentration and are a prescriber's responsibility — and getting them wrong is exactly the kind of error regulators flagged with non-standard products. The documented research and label doses (for example the 2.4 mg weekly weight-management maintenance dose) are described in milligrams on [the dosage page](/dosage) [1].

## What is compounded semaglutide?

Compounded semaglutide is semaglutide prepared by a compounding pharmacy rather than the approved manufactured product, permitted during a declared shortage from roughly 2022 to early 2025. Regulators documented dosing errors, hospitalizations, and products with unverified or non-pharmaceutical ingredients, and curtailed the pathway once the shortage resolved [5]. Compounded sources fall outside the approved-product evidence base the trials studied.

## What are the side effects of semaglutide?

The dominant side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation — mostly mild-to-moderate and transient, concentrated during dose escalation; a safety review reported nausea in roughly a third of patients [5][23]. Cited cautions include a thyroid C-cell boxed warning, a pancreatitis class warning, increased gallbladder disease, and retinopathy with rapid blood-sugar correction [5][2]. Full detail is on [the effects page](/effects).

## How long does it take for semaglutide to work?

Effects build gradually because the dose is escalated slowly over weeks. The pivotal weight result was measured at 68 weeks in STEP 1 (mean -14.9% vs -2.4% on placebo) [1], reflecting months of steady change rather than a sudden effect. Blood-sugar and appetite effects begin earlier, but the trials report their headline outcomes over many months.

## How long does semaglutide stay in your system?

A long time, by design. The elimination half-life is approximately one week (~165-168 hours), with effectively complete clearance roughly five weeks after the last dose [17]. This is why injection is once-weekly and why label guidance ties a multi-week washout before a planned pregnancy to the same half-life [17].

## What is the half-life of semaglutide?

Approximately one week — commonly cited as ~165-168 hours — for both the subcutaneous and oral forms, with near-complete clearance about five weeks after the final dose [17]. The long half-life comes from strong, reversible albumin binding via the fatty-acid side chain plus DPP-4 resistance from the position-8 substitution, the same features that enable once-weekly dosing.

## Is oral semaglutide as effective as the injection?

They are different formulations with their own trial programs. Oral semaglutide was noninferior to placebo for major cardiovascular events in PIONEER 6, with a numerically lower event rate [8], and higher oral doses (25 mg, 50 mg) improved glycemic control and weight versus 14 mg in PIONEER PLUS [11]. Oral bioavailability is low (~0.4-1%), so the fasted-dosing rule is strict [18].

## How long does it take for semaglutide to suppress appetite?

The trials report long-term outcomes rather than time-to-appetite-suppression, so a precise day cannot be cited. Mechanistically, the appetite effect is central: in rodents semaglutide acted on brain appetite circuits to reduce food intake and shift food preference [4]. People commonly describe reduced "food noise" early, but that is anecdotal — see [the effects page](/effects).

## Why am I not losing weight on semaglutide?

This site does not give individual medical guidance, so it cannot diagnose a personal response. For context, the trials report a mean weight change, not a uniform one: STEP 1 averaged -14.9% over 68 weeks, but an average spans a wide range of individual results [1]. Dose is escalated slowly over months, and effects accrue gradually. A prescriber is the right source for an individual situation.

## Does semaglutide make you tired?

Fatigue is reported in patient communities, especially in the first day or two after a dose and during early weeks, usually easing with time — but that is anecdotal, not a controlled-trial measure [5]. The trials' confirmed adverse-effect profile is dominated by gastrointestinal events rather than fatigue. Reported experiences are collected, labeled as anecdote, on [the effects page](/effects).

## Is semaglutide a GLP-1?

Yes. Semaglutide is a GLP-1 receptor agonist — a synthetic analogue of the gut hormone glucagon-like peptide-1 (GLP-1) that activates the same receptor [5]. It shares about 94% of native GLP-1's sequence but is engineered to resist the DPP-4 enzyme and to bind albumin, which is why it lasts about a week rather than minutes [17].

## Does semaglutide cause hair loss?

A pharmacovigilance analysis flagged a reporting signal for hair loss with semaglutide and a related drug [14], and a dermatology study linked telogen effluvium — a reversible, diffuse shedding — to the size and speed of weight loss [15]. The pattern fits weight-loss-driven shedding rather than a direct drug toxicity, and reports describe it as temporary.

## How fast does semaglutide work?

Not fast by design — the dose is stepped up slowly to limit early gut side effects, and the pivotal outcomes are measured over months. STEP 1 reported its mean -14.9% weight change at 68 weeks [1]. Blood-sugar and appetite effects start sooner, but the trials anchor their headline numbers to long follow-up rather than a quick result.

## What is the difference between semaglutide and tirzepatide?

Tirzepatide acts on two receptors (GIP and GLP-1); semaglutide acts on one (GLP-1). In the head-to-head SURMOUNT-5 trial (n=751) of adults with obesity, tirzepatide produced greater weight loss at 72 weeks (-20.2% vs -13.7%; P<0.001) [7]. Semaglutide's cardiovascular-outcome evidence base, anchored by SELECT and SUSTAIN-6, is the deeper of the two [3][2].

---

A naturalist's field notebook on the semaglutide trial record — observed, sequenced, and cited; not a clinic, not a prescriber, not a vendor.